1.10 lecture10

1.10 lecture10 - STAT 1301 Probability & Statistics $93,000...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
1 STAT 1301 Lecture 10 $93,000 cancer drug: How much is a life worth? The latest is Provenge, a first-of-a-kind therapy approved in April. It costs $93,000 a year and adds four months' survival, on average for men with incurable prostate average, for men with incurable prostate tumors. Celgene Corp.'s Revlimid pill for multiple myeloma, a type of blood cancer, can run as much as $10,000 a month; so can Genentech's Avastin for certain cancers. There's no rule on how much is too much Unlike drugs that people can try for a month or two and keep using only if they keep responding, Provenge is an all-or-nothing $93,000 gamble. It's a one- time treatment to train the immune system to fight prostate tumors, the first so-called cancer vaccine. At M.D. Anderson Cancer Center, doctors plan a lottery to decide which of its 150 patients will be among the two a month it can treat with Provenge. 12 days life? Doctors also have questioned the value of Genentech's Tarceva for pancreatic cancer. The $4,000-a-month drug won approval by
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 05/04/2011 for the course STAT 1301 taught by Professor Smslee during the Spring '08 term at HKU.

Page1 / 3

1.10 lecture10 - STAT 1301 Probability & Statistics $93,000...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online